Mankind Pharma Licenses Two Insulin Products, Expands Diabetes Portfolio
Mumbai: Mankind Pharma has entered into an exclusive in-licensing and marketing agreement with China-based Chongqing Chenan Biopharmaceutical for two insulin products in India. The agreement covers Insulin Degludec and a combination of Insulin Degludec and Insulin Aspart. Mankind Pharma will commercialise both injectable treatments in the Indian market. Diabetes portfolio expands The partnership…
We haven't written up this one. Free Press Journal has the full story — the link below goes straight to it.
